Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA.

Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-0135, USA.
Psychiatry Research (Impact Factor: 2.68). 08/2008; 163(2):171-82. DOI: 10.1016/j.pscychresns.2007.11.003
Source: PubMed

ABSTRACT Frontostriatal cognitive dysfunction is common in Parkinson disease (PD), but the explanation for its heterogeneous expressions remains unclear. This study examined the dopamine system within the frontostriatal circuitry with positron emission tomography (PET) to investigate pre- and post-synaptic dopamine function in relation to the executive processes in PD. Fifteen non-demented PD patients and 14 healthy controls underwent [(18)F]FDOPA (for dopamine synthesis) and [(11)C]NNC 112 (for D(1) receptors) PET scans and cognitive testing. Parametric images of [(18)F]FDOPA uptake (K(i)) and [(11)C]NNC 112 binding potential (BP(ND)) were calculated using reference tissue models. Group differences in K(i) and BP(ND) were assessed with both volume of interest and statistical parametric mapping, and were correlated with cognitive tests. Measurement of [(18)F]FDOPA uptake in cerebral cortex was questionable because of higher K(i) values in white than adjacent gray matter. These paradoxical results were likely to be caused by violations of the reference tissue model assumption rendering interpretation of cortical [(18)F]FDOPA uptake in PD difficult. We found no regional differences in D(1) receptor density between controls and PD, and no overall differences in frontostriatal performance. Although D(1) receptor density did not relate to frontostriatal cognition, K(i) decreases in the putamen predicted performance on the Wisconsin Card Sorting Test in PD only. These results suggest that striatal dopamine denervation may contribute to some frontostriatal cognitive impairment in moderate stage PD.


Available from: Vanessa Cropley, Jun 03, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Positron emission tomography (PET) has been widely used in the study of neurological and psychiatric disorders. It has been used most extensively in research to determine pathophysiology as well as prognostic and diagnostic information and response to various interventions in different disorders. PET imaging has also been used in the clinical setting, although its use has been primarily to help differentiate or diagnose specific disorders. With the continued development of a large array of radiopharmaceuticals that can evaluate all the components of different neurotransmitter systems (such as serotonin and dopamine), PET imaging will continue to play a key role in research and clinical applications for neurological and psychiatric disorders. © 2012 Wiley Periodicals, Inc. Int J Imaging Syst Technol, 22, 2–17, 2012 © 2012 Wiley Periodicals, Inc.
    International Journal of Imaging Systems and Technology 03/2012; 22(1):2-17. DOI:10.1002/ima.22004 · 0.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson's disease (PD) is characterized as a movement disorder due to lesions in the basal ganglia. As the major input region of the basal ganglia, striatum plays a vital role in coordinating movements. It receives afferents from the cerebral cortex and projects afferents to the internal segment of the globus pallidus and substantia nigra pars reticulate. Additionally, accumulating evidences support a role for synaptic dysfunction in PD. Therefore, the present study explores the changes in protein abundance involved in synaptic disorders in unilateral lesioned 6-OHDA rat model. Based on 18O/16O labeling technique, striatal proteins were separated using online two-dimensional liquid chromatography (2D-LC), and identified by nano-ESI-Q-TOF. A total of 370 proteins were identified including 76 significantly differentially expressed proteins. Twenty-two down-regulated proteins were found in composition of vesicle, 10 of which were involved in neuronal transmission and recycling across synapses. These include SNARE proteins (SNAP-25, syntaxin-1A, syntaxin-1B, VAMP2), synapsin-1, septin-5, clathrin heavy chain 1, AP-2 complex subunit beta, dynamin-1, and endophilin-A1. Moreover, mass spectrometry result for syntaxin-1A was confirmed by western blot analysis. Overall, these synaptic changes induced by neurotoxin may serve as a reference for understanding the functional mechanism of striatum in PD.This article is protected by copyright. All rights reserved
    Proteomics 08/2014; 14(15). DOI:10.1002/pmic.201400069 · 3.97 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background The hypothesis that cortical dopaminergic alterations underlie aspects of schizophrenia has been highly influential. Aims To bring together and evaluate the imaging evidence for dopaminergic alterations in cortical and other extrastriatal regions in schizophrenia. Method Electronic databases were searched for in vivo molecular studies of extrastriatal dopaminergic function in schizophrenia. Twenty-three studies (278 patients and 265 controls) were identified. Clinicodemographic and imaging variables were extracted and effect sizes determined for the dopaminergic measures. There were sufficient data to permit meta-analyses for the temporal cortex, thalamus and substantia nigra but not for other regions. Results The meta-analysis of dopamine D-2/D-3 receptor availability found summary effect sizes of d = -0.32 (95% CI -0.68 to 0.03) for the thalamus, d = -0.23 (95% CI -0.54 to 0.07) for the temporal cortex and d=0.04 (95% CI -0.92 to 0.99) for the substantia nigra. Confidence intervals were wide and all included no difference between groups. Evidence for other measures/regions is limited because of the small number of studies and in some instances inconsistent findings, although significant differences were reported for D-2/D-3 receptors in the cingulate and uncus, for D-1 receptors in the prefrontal cortex and for dopamine transporter availability in the thalamus. Conclusions There is a relative paucity of direct evidence for cortical dopaminergic alterations in schizophrenia, and findings are inconclusive. This is surprising given the wide influence of the hypothesis. Large, well-controlled studies in drug-naive patients are warranted to definitively test this hypothesis.
    The British journal of psychiatry: the journal of mental science 06/2014; 204(6):420-429. DOI:10.1192/bjp.bp.113.132308 · 7.34 Impact Factor